ArticleScience advances2025
Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Beyond pCR Prediction: Subtype-Specific Artificial Intelligence for Treatment Tailoring in Breast Cancer Neoadjuvant Therapy.Cancers · 2026Review
- The role of artificial intelligence in precision medicine for breast cancer.Discover oncology · 2026Review
- Predicting early-stage breast cancer disease-free survival and adjuvant therapy benefit from multimodal information using deep learning.NPJ breast cancer · 2026Article
- A weakly supervised deep learning-based recurrence prediction and risk stratification of lung adenocarcinoma from pathology whole-slide images.BMC cancer · 2026Article
- T2Pdecoder enables protein-centric analyses from transcriptomic data.Nature communications · 2026Article
- Artificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives.Breast cancer research : BCR · 2026Review
- Puerarin Reverses UV-Induced Epigenetic Silencing of the Wnt/β-Catenin-KIT Axis to Mitigate Skin Fibroblast Aging.International journal of molecular sciences · 2026Article
- Relationship Between Gut Microbiota and Cancer Neuro-Immunity.Microbial biotechnology · 2026Review
- Association of Post-Neoadjuvant Chemotherapy MRI andDiagnostics (Basel, Switzerland) · 2026Article
- A Knowledge-Enhanced Multimodal Framework with Genomic Reconstruction for DLBCL Drug Response Prediction.Computational and structural biotechnology journal · 2026Article
- A pretreatment 15-gene signature predicts non-pCR in response to neoadjuvant chemotherapy in breast cancer and reveals a pyruvate-Frontiers in oncology · 2026Article
- Identification of serum proteins associated with response of triple-negative breast cancer to neoadjuvant chemotherapy: preliminary results from the INSTIGO trial.Clinical proteomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.